Fracture healing with alendronate treatment in the Brtl/ plus mouse model of osteogenesis imperfecta

被引:19
|
作者
Meganck, J. A. [1 ,2 ]
Begun, D. L. [1 ,2 ]
McElderry, J. D. [3 ]
Swick, A. [1 ,2 ]
Kozloff, K. M. [1 ,2 ]
Goldstein, S. A. [1 ,2 ]
Morris, M. D. [3 ]
Marini, J. C. [4 ]
Caird, M. S. [1 ]
机构
[1] Univ Michigan, Dept Orthopaed Surg, Orthopaed Res Labs, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA
[4] NICHHD, Bone & Extracellular Matrix Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
Osteogenesis imperfecta; Bisphosphonates; Bone; Rodent; Fracture repair; HYPERPLASTIC CALLUS FORMATION; POLARIZED-LIGHT MICROSCOPY; ZOLEDRONIC ACID; BISPHOSPHONATE INCADRONATE; BONE STRENGTH; CHILDREN; PAMIDRONATE; COLLAGEN; REPAIR; RATS;
D O I
10.1016/j.bone.2013.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by increased skeletal fragility. Patients are often treated with bisphosphonates to attempt to reduce fracture risk. However, bisphosphonates reside in the skeleton for many years and long-term administration may impact bone material quality. Acutely, there is concern about risk of non-union of fractures that occur near the time of bisphosphonate administration. This study investigated the effect of alendronate, a potent aminobisphosphonate, on fracture healing. Using the Brtl/+ murine model of type IV OI, tibial fractures were generated in 8-week-old mice that were untreated, treated with alendronate before fracture, or treated before and after fracture. After 2, 3, or 5 weeks of healing, tibiae were assessed using microcomputed tomography (mu CT), torsion testing, quantitative histomorphometry, and Raman microspectroscopy. There were no morphologic, biomechanical or histomorphometric differences in callus between untreated mice and mice that received alendronate before fracture. Alendronate treatment before fracture did not cause a significant increase in cartilage retention in fracture callus. Both Brtl/+ and WT mice that received alendronate before and after fracture had increases in the callus volume, bone volume fraction and torque at failure after 5 weeks of healing. Raman microspectroscopy results did not show any effects of alendronate in wild-type mice, but calluses from Brtl+ mice treated with alendronate during healing had a decreased mineral-to-matrix ratio, decreased crystallinity and an increased carbonate-to-phosphate ratio. Treatment with alendronate altered the dynamics of healing by preventing callus volume decreases later in the healing process. Fracture healing in Brtl/+ untreated animals was not significantly different from animals in which alendronate was halted at the time of fracture. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:204 / 212
页数:9
相关论文
共 50 条
  • [41] Single dose of bisphosphonate preserves gains in bone mass following cessation of sclerostin antibody in Brtl/ plus osteogenesis imperfecta model
    Perosky, Joseph E.
    Khoury, Basma M.
    Jenks, Terese N.
    Ward, Ferrous S.
    Cortright, Kai
    Meyer, Bethany
    Barton, David K.
    Sinder, Benjamin P.
    Marini, Joan C.
    Caird, Michelle S.
    Kozloff, Kenneth M.
    BONE, 2016, 93 : 79 - 85
  • [42] Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta
    Shi, Changgui
    Hu, Bo
    Guo, Lei
    Cao, Peng
    Tian, Ye
    Ma, Jun
    Chen, Yuanyuan
    Wu, Huiqiao
    Hu, Jinquan
    Deng, Lianfu
    Zhang, Ying
    Yuan, Wen
    JOURNAL OF BONE AND MINERAL RESEARCH, 2016, 31 (05) : 1003 - 1014
  • [43] Osteoclast increases in the Brtl mouse model for osteogenesis imperfecta occur through marrow mesenchymal stromal cell dependent and independent mechanisms
    Maric, I.
    Smoljan, I.
    Turk, T.
    Celic, T.
    Cvek, S. Zoricic
    Orlic, Z. Crncevic
    Bobinac, D.
    BONE, 2011, 48 : S238 - S238
  • [44] TREATMENT OF OPEN FRACTURE OF THE FOREARM IN OSTEOGENESIS IMPERFECTA
    SCOTT, TR
    VANGIESEN, PJ
    JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 1989, 14A (01): : 111 - 114
  • [45] Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse
    Misof, BM
    Roschger, P
    Baldini, T
    Raggio, CL
    Zraick, V
    Root, L
    Boskey, AL
    Klaushofer, K
    Fratzl, P
    Carnacho, NP
    BONE, 2005, 36 (01) : 150 - 158
  • [46] Osteoclast increases in the Brtl mouse model for osteogenesis imperfecta occur through marrow mesenchymal stromal cell dependent and independent mechanisms
    Collin-Osdoby, P.
    Rothe, L.
    Kwong, M.
    Frigerio, B.
    Morinishi, L.
    Cabral, W. A.
    Osdoby, P.
    Marini, J. C.
    BONE, 2011, 48 : S238 - S238
  • [47] Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta
    Evans, KD
    Lau, ST
    Oberbauer, AM
    Martin, RB
    BONE, 2003, 32 (03) : 268 - 274
  • [48] Craniofacial Effects of Zoledronic Acid on the Osteogenesis Imperfecta Mouse (-/-) Model of Severe Osteogenesis Imperfecta
    Jeannerod, Gaspard
    Chretien, Antoine
    Andre, Gregoire
    Mabilleau, Guillaume
    Behets, Catherine
    BIOMEDICINES, 2024, 12 (12)
  • [49] Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta
    Roschger, Andreas
    Roschger, Paul
    Keplingter, Petra
    Klaushofer, Klaus
    Abdullah, Sami
    Kneissel, Michaela
    Rauch, Frank
    BONE, 2014, 66 : 182 - 188
  • [50] Metabolic phenotype in the mouse model of osteogenesis imperfecta
    Boraschi-Diaz, Iris
    Tauer, Josephine T.
    El-Rifai, Omar
    Guillemette, Delphine
    Lefebvre, Genevieve
    Rauch, Frank
    Ferron, Mathieu
    Komarova, Svetlana V.
    JOURNAL OF ENDOCRINOLOGY, 2017, 234 (03) : 279 - 289